Dishman Carbogen Amcis Limited - Asset Resilience Ratio
Dishman Carbogen Amcis Limited (DCAL) has an Asset Resilience Ratio of 5.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DCAL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Dishman Carbogen Amcis Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Dishman Carbogen Amcis Limited balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Dishman Carbogen Amcis Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Dishman Carbogen Amcis Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs6.16 Billion | 5.54% |
| Short-term Investments | Rs157.30 Million | 0.14% |
| Total Liquid Assets | Rs6.31 Billion | 5.68% |
Asset Resilience Insights
- Limited Liquidity: Dishman Carbogen Amcis Limited maintains only 5.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dishman Carbogen Amcis Limited Industry Peers by Asset Resilience Ratio
Compare Dishman Carbogen Amcis Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Dishman Carbogen Amcis Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Dishman Carbogen Amcis Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.35% | Rs354.30 Million ≈ $3.83 Million |
Rs99.99 Billion ≈ $1.08 Billion |
-1.42pp |
| 2024-03-31 | 1.77% | Rs1.70 Billion ≈ $18.38 Million |
Rs95.81 Billion ≈ $1.04 Billion |
-0.62pp |
| 2023-03-31 | 2.40% | Rs2.26 Billion ≈ $24.49 Million |
Rs94.53 Billion ≈ $1.02 Billion |
-1.59pp |
| 2022-03-31 | 3.98% | Rs3.44 Billion ≈ $37.22 Million |
Rs86.37 Billion ≈ $934.11 Million |
+1.74pp |
| 2021-03-31 | 2.24% | Rs1.88 Billion ≈ $20.29 Million |
Rs83.66 Billion ≈ $904.76 Million |
+0.60pp |
| 2020-03-31 | 1.64% | Rs1.35 Billion ≈ $14.57 Million |
Rs82.00 Billion ≈ $886.78 Million |
+1.00pp |
| 2019-03-31 | 0.64% | Rs471.10 Million ≈ $5.09 Million |
Rs73.28 Billion ≈ $792.55 Million |
-1.08pp |
| 2018-03-31 | 1.73% | Rs1.24 Billion ≈ $13.40 Million |
Rs71.76 Billion ≈ $776.11 Million |
+1.42pp |
| 2017-03-31 | 0.30% | Rs199.20 Million ≈ $2.15 Million |
Rs65.93 Billion ≈ $713.05 Million |
+0.18pp |
| 2016-03-31 | 0.12% | Rs36.30 Million ≈ $392.57K |
Rs29.81 Billion ≈ $322.33 Million |
-0.35pp |
| 2015-03-31 | 0.47% | Rs132.00 Million ≈ $1.43 Million |
Rs28.13 Billion ≈ $304.22 Million |
+0.47pp |
| 2013-03-31 | 0.00% | Rs117.00K ≈ $1.27K |
Rs23.15 Billion ≈ $250.35 Million |
-0.20pp |
| 2012-03-31 | 0.21% | Rs46.13 Million ≈ $498.86K |
Rs22.49 Billion ≈ $243.22 Million |
-0.07pp |
| 2011-03-31 | 0.27% | Rs56.35 Million ≈ $609.41K |
Rs20.82 Billion ≈ $225.19 Million |
+0.27pp |
| 2008-03-31 | 0.00% | Rs-1.00K ≈ $-10.81 |
Rs14.70 Billion ≈ $158.94 Million |
-0.36pp |
| 2005-03-31 | 0.36% | Rs11.65 Million ≈ $126.00K |
Rs3.22 Billion ≈ $34.84 Million |
-- |
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more